NextCure Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 40

Employees

  • Stock Symbol
  • NXTC

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $6.89
  • (As of Thursday Closing)

NextCure General Information

Description

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 9000 Virginia Manor Road
  • Suite 200
  • Beltsville, MD 20705
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 9000 Virginia Manor Road
  • Suite 200
  • Beltsville, MD 20705
  • United States
+1 (240)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NextCure Stock Performance

As of 19-Nov-2026, NextCure’s stock price is $6.89. Its current market cap is $31M with 4.58M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.89 $6.88 $1.55 - $15.74 $31M 4.58M 79.6K -$6.78

NextCure Financials Summary

As of 30-Sep-2026, NextCure has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,448 25,046 (48,327) (80,277)
Revenue 0 0 0 0
EBITDA (40,050) (53,644) (52,754) (59,023)
Net Income (40,970) (55,844) (55,654) (62,723)
Total Assets 9,700 50,183 80,860 128,038
Total Debt 0 5,153 5,949 6,605
Public Fundamental Data provided by Morningstar, Inc. disclaimer

NextCure Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NextCure‘s full profile, request access.

Request a free trial

NextCure Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore NextCure‘s full profile, request access.

Request a free trial

NextCure Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat c
Drug Discovery
Beltsville, MD
40 As of 2025

San Francisco, CA
 

La Jolla, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NextCure Competitors (132)

One of NextCure’s 132 competitors is Nurix Therapeutics, a Formerly VC-backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nurix Therapeutics Formerly VC-backed San Francisco, CA
Inhibrx Formerly VC-backed La Jolla, CA
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN
Kyntra Bio Formerly VC-backed San Francisco, CA
Xenetic Biosciences Corporation Framingham, MA
You’re viewing 5 of 132 competitors. Get the full list »

NextCure Patents

NextCure Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025245146-A2 Anti-apoe antibodies: compositions and methods of making and using the same Pending 20-May-2024
WO-2025245146-A3 Anti-apoe antibodies: compositions and methods of making and using the same Pending 20-May-2024
WO-2025155809-A2 Compositions and methods for modulating vstm-1 mediated signal transduction Pending 18-Jan-2024
WO-2025155809-A3 Compositions and methods for modulating vstm-1 mediated signal transduction Pending 18-Jan-2024
WO-2025137236-A1 Compositions and methods for modulating cdcp1 mediated signal transduction Inactive 21-Dec-2023 A61K47/6849
To view NextCure’s complete patent history, request access »

NextCure Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NextCure Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NextCure‘s full profile, request access.

Request a free trial

NextCure Acquisitions (1)

NextCure’s most recent deal was a Reverse Merger with Avere Therapeutics for . The deal was made on 14-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Avere Therapeutics 14-Jul-2026 Reverse Merger Drug Discovery
To view NextCure’s complete acquisitions history, request access »

NextCure ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.13 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view NextCure’s complete esg history, request access »

NextCure Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
NextCure (40,000 Square Foot GMP Biologics Manufacturing Facility) Beltsville, MD

NextCure FAQs

  • When was NextCure founded?

    NextCure was founded in 2015.

  • Where is NextCure headquartered?

    NextCure is headquartered in Beltsville, MD.

  • What is the size of NextCure?

    NextCure has 40 total employees.

  • What industry is NextCure in?

    NextCure’s primary industry is Drug Discovery.

  • Is NextCure a private or public company?

    NextCure is a Public company.

  • What is NextCure’s stock symbol?

    The ticker symbol for NextCure is NXTC.

  • What is the current stock price of NextCure?

    As of 19-Nov-2026 the stock price of NextCure is $6.89.

  • What is the current market cap of NextCure?

    The current market capitalization of NextCure is $31M.

  • Who are NextCure’s competitors?

    Nurix Therapeutics, Inhibrx, Apexian Pharmaceuticals, Kyntra Bio, and Xenetic Biosciences are some of the 132 competitors of NextCure.

  • What is NextCure’s annual earnings per share (EPS)?

    NextCure’s EPS for 12 months was -$6.78.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process